Clinical Trials Logo

Haemodynamic Rebound clinical trials

View clinical trials related to Haemodynamic Rebound.

Filter by:
  • None
  • Page 1

NCT ID: NCT02271555 Not yet recruiting - Clinical trials for Haemodynamic Rebound

The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy

Start date: October 2014
Phase: Phase 4
Study type: Interventional

The investigators will be evaluated the effects of a single loading dose of remifentanil (1µg/kg), administered as an adjunct to sevoflurane, on duration of hemodynamic profile, seizure activity, and recovery times during electroconvulsive therapy (ECT) in patients with major depression

NCT ID: NCT02139631 Completed - Clinical trials for Haemodynamic Rebound

Hemodynamic Repercussions of Noninvasive Ventilation

Start date: May 2014
Phase: N/A
Study type: Interventional

The noninvasive ventilation (NIV) is a method of ventilatory support that does not require artificial airway. Its application is associated with complex hemodynamic repercussions, therefore is important to identify them for safety and effectiveness of the technique application. The main objective of this research is to evaluate the hemodynamic repercussions using doppler echocardiography in healthy volunteers submitted a different values of positive end expiratory pressure (PEEP) by the following ventilatory modes: Continuous positive airway pressure (CPAP) and Bilevel. The study hypothesis is that the positive end expiratory pressure (PEEP) may cause hemodynamic repercussions as: reduction of the ventricles pre-load, left ventricle after load, cardiac output and reduction in the diameter of the superior vena cava, due to the increase in the intrathoracic pressure and pulmonary volumes.

NCT ID: NCT01611181 Completed - Clinical trials for Haemodynamic Rebound

Iron Substitution After Total Knee Arthroplasty

Start date: May 2006
Phase: Phase 1
Study type: Interventional

Hemoboost is a registered natural product containing specially processed haemolysed haemoglobin and iron dextran. It is marketed for human use on the basis of many years' use and documented effect in veterinary medicine. Iron dextran was introduced for use in human medicine in 1954. Krauterblut is a registered natural product made from a number of herbs where the active substance is ferrous gluconate. Both drugs have been available for a number of years and have become increasingly popular among patients and healthcare staff due to a reduction in adverse effects. The objective of this study is to determine the effect and adverse effects of the natural products Hemoboost and Kräuterblut compared with the usually administered ferrous sulphate in knee arthroplasty.